Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VBI Vaccines
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
An insomnia drug to improve daytime functioning, a treatment for a rare type of eye cancer, and an oral migraine drug for both acute and preventive treatment are among 13 new products recommended for pan-EU approval.
The European Medicines Agency will likely decide this week whether to recommend for pan-EU approval new treatments for insomnia, uveal melanoma, migraine and advanced prostate cancer.
ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Large Molecule
- Other Names / Subsidiaries
- Variation Biotechnologies